Li Qinchen, Wang Zhize, Yi Jiahe, Shen Haixiang, Yang Zitong, Yan Libin, Xie Liping
Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang Province 310003, China.
Cancer center, Zhejiang University, Hangzhou, Zhejiang Province 310058, China.
Transl Oncol. 2021 Sep;14(9):101145. doi: 10.1016/j.tranon.2021.101145. Epub 2021 Jun 12.
Studies have shown that AR-V7 may be correlated with the poor prognosis of castration resistant prostate cancer (CRPC), however, clinicopathological characteristics of AR-V7 have not been fully elucidated.
This study aimed at evaluating the clinicopathological features of AR-V7 in CRPC patients.
To evaluate the clinicopathological features of AR-V7 in CRPC patients. A search of PubMed, Embase, and Web of Science was performed using the keywords prostate cancer, prostate tumor, prostate neoplasm, prostate carcinoma, AR-V7, AR3, androgen receptor splicing variant-7, or androgen receptor-3. Twenty-four trials published by February 2020 were included in this study.
The proportion of Gleason score ≥ 8 was found to be significantly higher in AR-V7-positive CRPC (69.5%) than negative (54.9%) (OR 1.68, 95% CI 1.25-2.25, p < 0.001), while the rates of T3/T4 stage (OR 1.16, 95% CI 0.60-2.24, p = 0.65) and N1 stage (OR 0.99, 95% CI 0.65-1.51, p = 0.96) were not statistically correlated with AR-V7 status. The AR-V7-positive patients exhibited a significantly higher proportion of any site metastasis (61.3% versus 35.0%; OR 2.19, 95% CI 1.57-3.05, p < 0.001) and bone metastasis (81.7% versus 69.0%; OR 1.97, 95% CI 1.44-2.69, p < 0.001), and a trend close to significance was expected in visceral metastasis (28.8% versus 22.1%; OR 1.29, 95% CI 0.96-1.74, p = 0.09). Incidences of pain in AR-V7-positive CRPC (54.6%) were significantly higher than in negative CRPC (28.1%; OR 4.23, 95% CI 2.52-7.10, p < 0.001), line with worse ECOG performance status (56.7% versus 35.0%, OR 2.18, 95% CI 1.51-3.16, P < 0.001). Limitations of the study include differences in sample sizes and designs, AR-V7 detection assays, as well as disease characteristics of the included studies.
AR-V7 positivity is associated with a higher Gleason score, bone or any site metastasis, pain and worse ECOG performance scores in CRPC. However, it is not correlated with tumor stage or lymph node metastasis. More studies are needed to confirm these findings.
研究表明，AR-V7可能与去势抵抗性前列腺癌（CRPC）的不良预后相关，然而，AR-V7的临床病理特征尚未完全阐明。
本研究旨在评估CRPC患者中AR-V7的临床病理特征。
为评估CRPC患者中AR-V7的临床病理特征。使用关键词前列腺癌、前列腺肿瘤、前列腺肿物、前列腺癌、AR-V7、AR3、雄激素受体剪接变体-7或雄激素受体-3在PubMed、Embase和Web of Science上进行检索。纳入了截至2020年2月发表的24项试验。
发现AR-V7阳性的CRPC患者中Gleason评分≥8的比例（69.5%）显著高于阴性患者（54.9%）（OR 1.68，95%CI 1.25 - 2.25，p<0.001），而T3/T4期（OR 1.16，95%CI 0.60 - 2.24，p = 0.65）和N1期（OR 0.99，95%CI 0.65 - 1.51，p = 0.96）的发生率与AR-V7状态无统计学相关性。AR-V7阳性患者出现任何部位转移（61.3%对35.0%；OR 2.19，95%CI 1.57 - 3.05，p<0.001）和骨转移（81.7%对69.0%；OR 1.97，95%CI 1.44 - 2.69，p<0.001）的比例显著更高，内脏转移（28.8%对22.1%；OR 1.29，95%CI 0.96 - 1.74，p = 0.09）有接近显著的趋势。AR-V7阳性的CRPC患者疼痛发生率（54.6%）显著高于阴性CRPC患者（28.1%；OR 4.23，95%CI 2.52 - 7.10，p<0.001），与较差的美国东部肿瘤协作组（ECOG）体能状态一致（56.7%对35.0%，OR 2.18，95%CI 1.51 - 3.16，P<0.001）。本研究的局限性包括样本量和设计、AR-V7检测方法以及纳入研究的疾病特征方面的差异。
AR-V7阳性与CRPC患者更高的Gleason评分、骨或任何部位转移、疼痛以及更差的ECOG体能评分相关。然而，它与肿瘤分期或淋巴结转移无关。需要更多研究来证实这些发现。
Zotero 插件
